The Drugs Controller General of India (DCGI) has approved drug 2-deoxy-D-glucose (2-DG) for emergency use as an adjunct therapy in moderate to severe Covid-19 cases.
According to reports, the drug has been developed by DRDO Lab Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy’s Laboratories. Clinical trials have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
In a tweet written by PIB India it read, “Drugs Controller General of India approves anti-COVID drug developed by @DRDO_India for emergency use. Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence.”
India on Friday reported over 4.01 lakh new coronavirus infections with over 4,000 new deaths.